The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy
Kidney International · 2023
DOI: 10.1016/j.kint.2023.09.003 ↗Kurz gefasst
Kommentar in der Zeitschrift Kidney International, 2023. Verfasst von Laurence H Beck. Beteiligte Einrichtung: Nephrology Section, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. Electronic ad…. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Much akin to the explosion in number of known target antigens in membranous nephropathy, there has been a rapid expansion in the availability of animal models involving the first 2 antigens discovered in adult disease, phospholipase A2 receptor and thrombospondin type 1 domain-containing 7A. In this issue, Tomas et al. describe a novel mouse model of phospholipase A2 receptor-associated membranous nephropathy that shows great promise for investigating molecular mechanisms of disease and as an experimental system for testing existing and emerging therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nephrology Section, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. Electronic address: laurence.beck@bmc.org.
Zitieren
APA
Beck, L. H. (2023). The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy. Kidney International. https://doi.org/10.1016/j.kint.2023.09.003
Vancouver
Beck LH. The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy. Kidney International. 2023. doi:10.1016/j.kint.2023.09.003
BibTeX
@article{Beck2023,
author = {Beck, Laurence H},
title = {The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy},
journal = {Kidney International},
year = {2023},
doi = {10.1016/j.kint.2023.09.003}
}
EUVIMED